COMP <GO>
VCYT vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Veracyte Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: VCYT 6
— JNJ 6
■ METRIC PARITY
LAST: $50.01 (-4.14%) • MKT CAP: $4.19B
options-implied-move
7.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
options-implied-move
7.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCYT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCYT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.10% | 67.90% | +2.20 | VCYT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 25.50% | -20.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 58.7x | 18.5x | +40.20 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.02% | 2.97% | +0.05 | VCYT | /fcf-yield <GO> |
| Operating Margin | 11.20% | 34.70% | -23.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 12.80% | 28.50% | -15.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 16.00% | 6.00% | +10.00 | VCYT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | VCYT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | VCYT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.9 | 60.4 | +0.57 | VCYT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 53.1x | 23.0x | +30.10 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.19B | $662.49B | -$658.30B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCYT REV | JNJ REV | VCYT GROSS % | JNJ GROSS % | VCYT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $517.1M | $94.19B | 70.1% | 67.9% | $126.6M | $19.70B |
| FY 2024 | $445.8M | $88.82B | 66.9% | 69.1% | $63.8M | $19.84B |
| FY 2023 | $361.1M | $85.16B | 44.0% | 44.0% | $28.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCYT // BETA 1.08
JNJ // BETA 1.08